XM无法为美国居民提供服务。
S
S

Sage

交易方向

交易者偏好

技术摘要

每小时

市场新闻

Sage Therapeutics falls after Biogen terminates tremor drug partnership

BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership ** Shares of drug developer Sage Therapeutics SAGE.O fall 1% to $6.95 premarket ** Company says partner Biogen BIIB.O has terminated a licensing deal for Sage's experimental drug to treat essential tremor, effective February 2025 ** Sage had discontinued development of the
B
S

SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program

BRIEF-SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program Sept 26 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES DISCONTINUATION OF THE COLLABORATION WITH BIOGEN ON THE SAGE-324 PROGRAM SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER SAGE-324 PROGRAM SAGE THERAPEUTICS I
S

Incorrect research alert on Sage Therapeutics Inc withdrawn

ADVISORY-Incorrect research alert on Sage Therapeutics Inc withdrawn An alert on J.P. Morgan cutting its price target on Sage Therapeutics Inc SAGE.O is incorrect and has been withdrawn. The brokerage lowered its PT on Sage Group PLC, an unrelated company. For the correct research alert on Sage Group PLC, click here . STORY_NUMBER: FWN3L714D STORY_
S

U.S. CH Robinson Worldwide, Dayforce, Entegris

U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Dayforce, Entegris Aug 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CH Robinson Worldwide, Dayforce and Entegris, on Thursday. HIGHLIGHTS * CH Robinson Worldwide Inc CHRW.O : JP Morgan raises to overweight from neutral * Dayforce Inc DAY.N : Piper Sandler raises to overweight from neutral * Entegris Inc ENTG.O : Seaport Research Partners raises to buy from neutral * M
B
C
D
E
M
Q
S
V
A
C
D
E
L
T
P
W
A
B
C

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.70​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-2.68. The mean expectation of twenty analysts for the quarter was for a loss of $1.66 per share.
S

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明